Taka Maeda<p>Why not in Japan? @PMDA_JPN <br />---<br />RT @AML_Hub<br />🚨 NEWS 🚨<br />Oral ivosidenib, an IDH1 inhibitor, receives a positive opinion from the CHMP of the EMA for the treatment of patients with IDH1-mutated AML. This opinion is based on data from the AGILE trial.<br /><a href="https://loom.ly/7yv6z94" target="_blank" rel="nofollow noopener noreferrer" translate="no"><span class="invisible">https://</span><span class="">loom.ly/7yv6z94</span><span class="invisible"></span></a> <br /><a href="https://mstdn.science/tags/leusm" class="mention hashtag" rel="tag">#<span>leusm</span></a> <a href="https://mstdn.science/tags/mednews" class="mention hashtag" rel="tag">#<span>mednews</span></a> <br /><a href="https://twitter.com/AML_Hub/status/1630569392202194944" target="_blank" rel="nofollow noopener noreferrer" translate="no"><span class="invisible">https://</span><span class="ellipsis">twitter.com/AML_Hub/status/163</span><span class="invisible">0569392202194944</span></a></p>